Head and neck tumour immunology: Basic concepts and new clinical implications

Journal of Laryngology and Otology

Volumn 123, Issue 1, 2009, Pages 9-18

  Topping, K P ^a   Fletcher, L M ^a   Agada, F O ^a   Alhamarneh, O ^a   Stafford, N D ^a   Greenman, J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Head and Neck Neoplasms; Immunology

Indexed keywords

CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; COMPLEMENT;

B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; INNATE IMMUNITY; LYMPHATIC SYSTEM; MONONUCLEAR CELL; NATURAL KILLER CELL; PHAGOCYTE; POLYMORPHONUCLEAR CELL; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; BONE MARROW CELL; HEAD AND NECK TUMOR; IMMUNOLOGY; LYMPHOCYTE;

CARCINOMA, SQUAMOUS CELL; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULINS; LYMPHOCYTES; MYELOID CELLS;

EID: 64249168539     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215108003368     Document Type: Review

References (41)

1. Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt's Essential Immunology, 11th edn. Oxford: Blackwell, 2006
2. Bernard A, Boumsell L. The clusters of differentiation (CD) defined by the first international workshop on human leukocyte differentiation antigens. Hum Immunol 1984;11:1-10
3. Zola H, Swart B, Banham A, Barry S, Beare A, Bensussan A et al. CD molecules 2006 - human cell differentiation molecules. J Immunol Meth 2007;319:1-5
4. Douglas WG, Tracy E, Tan D, Yu J, Hicks WL Jr, Rigual NR et al. Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res 2004;2:585-93
5. Pries R, Thiel A, Brocks C, Wollenberg B. Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma. In Vivo 2006;20:45-8
6. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev 2006;17:141-6
7. Lathers OM, Young MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squa- mous cell carcinoma of the head and neck. Cytokine 2004; 25:220-8
8. Druzgal CH, Chen Z, Yeh NT, Thomas GR, Ondrey FG, Duffey DC et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck 2005;27:771-84
9. van Herpen CM, van del' Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG et al. Intratu- moral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies loco regional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clinical Cancer Res 2005;11:1899-909
10. Nakano H, Kishida T, Asada H, Shin-Ya M, Shinomiya T, Imanishi J et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antit- umor effects against head and neck squamous cell carcinoma. J Gene Med 2006;8:90-9
11. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62
12. Karcher J, Reisser C, Daniel V, Herold-Mende C. Cyto- kine expression of transforming growth factor-beta 2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels [in German]. HNO 1999;47:879-84
13. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of TH1/TH2 responses. Semin Immunol 2001;13:275-82
14. Dunn G, Oliver KM, Loke D, Stafford ND, Greenman J. Dendritic cells and HNSCC: a potential treatment option? Oncol Rep 2005;13:3-10
15. Palucka KA, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-50
16. Nicolette CA, Healey D, Tcherepanova I, Whelton P, Monesmith T, Coombs L et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007;25(Suppl 2):B47-60
17. Agada FO, Alhamarneh O, Stafford ND, Greenman J. Immunotherapy in head and neck cancer: Current practice and future possibilities. J Laryngol Otol (in press)
18. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK. An immunohistochemical study of altered immuno- modulatory molecule expression in head and neck squa- mous cell carcinoma. Br J Cancer 1997;76:836- 44
19. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205
20. Sparano A, Lathers D, Achille N, Petruzzelli GJ, Young MRI. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004;131:573- 6
21. Jebreel A, Mistry D, Lake D, Dunn G, Hough V, Oliver K et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 2007;121:246-52
22. Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses in the tumor. Curr Cancer Drug Targets 2007;7:633-42
23. Shevach EM. Regulatory/suppressor T cells in health and disease. Arthritis Rheum 2004;50:2721 -4
24. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77
25. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. Localisation pattern of Foxp3 regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008;98:148-53
26. + Treg
27. clones obtained from peripheral blood of patients with cancer. Int J Can 2007;121:2473-83
28. Alhamarneh O, Amarnath SMP, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 2008;30:251-61
29. Fanning LJ, Connor AM, Wu GE. Development of immunoglobulin repertoire. Clin Immunol Immunopathol 1996; 79:1-14
30. Liu X-Y, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008;222:9-27
31. Iannello A, Ahmad A. Role of antibody-dependent cell- mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005;24:487-99
32. Bonner JA, Harari PM, Giralt J, Azarnian N, Shin DM, Cohen RB et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006;354:567-78
33. Bose A, Baral R. IFNalpha2b stimulated release of IFN- gamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity. Immunol Lett 2007;108:68-77
34. González FM, Vargas JA, Lcj́pez-Cortijo C, CasteṕnR, Gorriz C, Ramírez-Camacho R et al. Prognostic significance of natural killer cell activity in patients with laryn- geal carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124:852-6
35. Heimdal JH, Aarstad HJ, Klementsen B, Olofsson J. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumour stage and prognosis. Acta Otolaryngol 1999;119:281-4
36. Costain DJ, Guha AK, Liwski RS, Lee TD. Murine hypo- dense eosinophils induce tumour cell apoptosis bya granzyme B-dependent mechanism. Cancer Immunol Immunother 2001;50:293-9
37. Goldsmith MM, B elchis DA, Cresson DH, Merritt WD 3rd, Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992;106:27-33
38. Alrawi SJ, Tan D, Stoler DL, Dayton M, Anderson GR, Mojica P et al. Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locore- gional recurrence in head and neck squamours neoplasia. Cancer J 2005:11;217-25
39. Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007;111:6-13
40. Ravindranath NMH, Shuler C. Expression of complement restriction factors (CD46, CD55 and CD59) in head and neck squamous cell carcinomas. J Oral Path Med 2006;35:560-7
41. Caragine TA, Okada N, Frey AB, Tomlinson S. A tumor- expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res 2002;62:1110-15